FDA approves Lorcaserin and Mirabegron extended-release tablets.
Craig I. Coleman, PharmD
Advertisement
Articles by Craig I. Coleman, PharmD
FDA has approved pancrelipase delayed-release capsules to treat exocrine pancreatic insufficiency resulting from cystic fibrosis or other conditions.
FDA approves avanafil and tafluprost
FDA approves Lucinactant and Peginesatide
Advertisement
Latest Updated Articles
- Pancrelipase DR caps approved for EPI
August 10th 2012
- New treatments for obesity and OAB
September 15th 2012
- FDA approves oral inhibitor for ED
July 15th 2012
- Lucinactant approved for premie RDS
June 15th 2012
Advertisement
Advertisement
Trending on Drug Topics
1
Study Identifies Patients at Risk for Severe COVID-19 Post-Vaccination
2
Zepbound Lowers Health Care Costs in Older Adults With Obesity
3
Measles Resurgence Exposes US Vaccine Policy Risks, Experts Warn
4
Ixekizumab, Tirzepatide Maintains Efficacy in Psoriatic Disease
5